viewAllergy Therapeutics PLC

Allergy Therapeutics outperforming the market "significantly" in latest financial year

Allergy Therapeutics

Allergy Therapeutics plc's (LON:AGY) Nick Wykeman and Manuel Llobet tell Proactive the company has continued to take market share and is "outperforming the market significantly" as the firm releases its figures for the latest financial year.

The group said the year to the end of June was one of strong progress made against its strategic objectives of expanding in Europe, preparing for entry into the US market, and making clinical progress with the group's lead assets.

Despite a low pollen season, revenue rose 6.6% to £68.3mln from £64.1mln the year before, albeit helped by currency movements; on a constant currency (CC) basis, revenue growth was 3.5%.

Quick facts: Allergy Therapeutics PLC

Price: 11.15 GBX

Market: AIM
Market Cap: £70.93 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...



Allergy Therapeutics confident on the coming year as it reports 8% boost to...

Allergy Therapeutics PLC's (LON:AGY) Manuel Llobet and Nick Wykeman talk Proactive London's through the firm's preliminary results to June 2019. The vaccines specialist posted an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of...

on 25/9/19

2 min read